HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
For normal-risk, newly diagnosed myeloma patients, which triple drug combination is more effective?
Posted: Dec 11, 2013
For normal-risk, newly diagnosed myeloma patients, which triple drug combination is more effective? image

This is a randomized Phase III trial (half of the patients receive one combination and half receive the other combination) to determine which combination is a better starting approach for a newly diagnosed myeloma patient with active disease. Is VRD (bortezomib, lenalidomide and dexamethasone) better or is CRD (carfilzomib, lenalidomide and dexamethasone) better? Each group receives one of the two combinations and then are both given lenalidomide maintenance therapy indefinitely. This is called the ENDURANCE trial by investigators and is looking to recruit 756 patients that are not considered high-risk. This trial assumes that stem cell transplant will NOT be used as an up-front therapy. Learn more >

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube